Minerva Neurosciences Inc Company Profile
NASDAQ: NERVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:46 PM ET
Minerva Neurosciences at a glance
Minerva Neurosciences Inc (NASDAQ: NERV) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Burlington, MA. Minerva Neurosciences is led by Dr. Remy Luthringer Ph.D. and employs about 7 people. The company's shares have traded publicly since 2014.
At a market capitalization of $156.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001598646, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Minerva Neurosciences do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Minerva Neurosciences Inc
- Ticker
- NASDAQ: NERV
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Remy Luthringer Ph.D.
- Employees
- 7
- Headquarters
- 1500 District Avenue, Burlington, MA, United States
- Phone
- 617 600 7373
- Website
- minervaneurosciences.com
- IPO year
- 2014
- Market cap
- $156.13M
- SEC CIK
- 0001598646
- Latest annual report
- 10-K · Mar 11, 2026
Companies similar to Minerva Neurosciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRROKorro Bio Inc. | 10.54 | +0.48% | $155.21M | vs NERV |
| MSLESatellos Bioscience Inc. | 7.31 | -4.19% | $155.09M | vs NERV |
| NBPNovaBridge Biosciences ADR | 1.36 | -0.73% | $157.76M | vs NERV |
| MENSJyong Biotech Ltd. | 2.03 | -0.98% | $154.34M | vs NERV |
| NKTXNkarta Inc. | 2.21 | -2.64% | $158.29M | vs NERV |
| VRXAVeraxa Biotech AG | 1.13 | -6.25% | $159.08M | vs NERV |
| EMISEmmis Acquisition Corp. Class A | 10.27 | 0.00% | $162.02M | vs NERV |
| CUECue Biopharma Inc. | 22.35 | -0.74% | $162.32M | vs NERV |